Targeted therapeutics drug discovery and development company Arrien Pharmaceuticals has entered a worldwide license agreement with an unnamed US-based pharmaceutical firm for the clinical agent ARN-6039.
ARN-6039 will be developed for the potential treatment of moderate to severe psoriasis, as well as other autoimmune disorders.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Psoriasis is a common chronic autoimmune disorder of the skin that affects approximately 3% or 125 million people worldwide.
Enhanced activity of TH17 (T helper 17) cells, and the associated excess production of pro-inflammatory cytokines, including IL-17 and IL-17A, are major elements responsible for the pathophysiology of psoriasis.
The current license agreement involves the clinical agent ARN-6039, in addition to Arrien Pharmaceuticals’ series of ROR-γt targeting compounds.
Before signing the licensing agreement, the company has completed a single US centre Phase I clinical trial that demonstrated the safety, tolerability and pharmacokinetics of single ascending doses of ARN-6039 in healthy adults.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe partnership of ARN-6039 at the Phase I stage of development validates Arrien’s small molecule fragment-based discovery platform (FIELDS).
ARN-6039 is an inverse agonist of ROR-γt, a transcription factor that regulates TH17 and the generation of IL-17 and IL-17A, pro-inflammatory cytokines that are important for the immunopathology of autoimmune diseases, including psoriasis.
Inhibition of ROR-γt has been demonstrated both pre-clinically and clinically to have efficacy in the treatment of multiple autoimmune disorders.
The ARN-6039 was discovered through Arrien Pharmaceuticals’ FIELDS drug discovery technology platform.
